Avaliação dos casos de osteonecrose dos maxilares associados ao uso drogas antirreabsortivas
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Avaliar os casos de osteonecrose dos maxilares associados ao uso de drogas antirreabsortivas atendidos no ambulatório de Cirurgia Bucomaxilofacial. Métodos: Estudo retrospectivo, de delineamento transversal, com abordagem quantitativa, de caráter descritivo. Os dados foram extraídos a partir de consultas aos prontuários físico, tabulados em planilhas do Microsoft Excel e analisados no Statistical Package for Social Sciences. Resultados: A amostra contou com 10 indivíduos, com prevalência do sexo feminino (90%), com faixa etária igual ou superior a 60 anos. O alendronato foi a droga mais utilizada (60%), a via oral foi a mais empregada com 90% dos casos e o tempo de exposição à medicação de 4 a 5 anos. O estágio 2 da osteonecrose prevaleceu em 60% dos indivíduos, apresentando-se como principal localização a mandíbula (80%), com abordagem por tratamentos cirúrgicos e não-cirúrgicos. Conclusão: A terapia prolongada associada a condições sistêmicas aumenta o risco do desenvolvimento da doença e tornam-se fatores agravantes no tratamento.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. AREDE DP, et al. Osteonecrosis of the jaw with the use of bisphosphonates and treatment with laser therapy and magnetotherapy: a concise systematic review. MedNEXT Journal of Medical and Health Sciences, 2023; 4(2).
3. ASSILI Z, et al. A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva®) Related Osteonecrosis of the Jaw: A Retrospective Study. Journal of Clinical Medicine, 2021; 10(11): 2390.
4. BANSAL H. Osteonecrose da mandíbula relacionada a medicamentos: uma atualização. Revista Nacional de Cirurgia Maxilofacial, 2022; 13(1): 5.
5. BEDOGNI A, et al. Italian position paper (SIPMO‐SICMF) on medication‐related osteonecrosis of the jaw (MRONJ). Oral Diseases, 2024.
6. BRZAK BL, et al. Osteonecrose da mandíbula. Revista Odontologia, 2023; 11(1):23.
7. DIAS AA, et al. A Fotobiomodulação como alternativa no tratamento da osteonecrose dos maxilares relacionada à medicamentos: uma revisão da literatura. Revista Científica FACS, 2023; 23(2): 01-09.
8. DIAS KS, et al. Bisphosphonate-associated osteonecrosis of the jaw in oncology patient: case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology,2024; 137(6): e247.
9. EGUIA A, et al. Review and update on drugs related to the development of osteonecrosis of the jaw. Medicina oral, patologia oral y cirugia bucal, 2020; 25(1): e71.
10. GIUDICE A, et al. The case of medication-related osteonecrosis of the jaw addressed from a pathogenic point of view. Innovative therapeutic strategies: Focus on the most recent discoveries on oral mesenchymal stem cell-derived exosomes. Pharmaceuticals, 2020; 13(12): 423.
11. GUPTA M, GUPTA N. Bisphosphonate Related Jaw Osteonecrosis. StatPearls Publishing; 2024.
12. HANNA R, et al. A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials. Pharmaceuticals, 2024; 17(8): 1011.
13. HOCHMULLER M. et al. Diagnóstico, tratamento e prevenção da osteonecrose maxilar relacionada a medicamentos. Revista Brasileira Multidisciplinar, 2021; 24(2):233-247.
14. IZZETTI R, et al. Panoramic Radiography Features of Medication‐Related Osteonecrosis of the Jaws (MRONJ). International Journal of Dentistry, 2023; 2023(1): 5358849.
15. KAWAHARA M, et al. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. International journal of implant dentistry,2021; 7(1): 47.
16. KO YY, et al. The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ). Diagnostics, 2024; 14(16): 1700.
17. KUROSHIMA S, et al. Medication‐related osteonecrosis of the jaw: a literature review and update. Genesis, 2022; 60(8-9): 23500.
18. KWOEN M, et al. Association between periodontal disease, tooth extraction, and medication‐related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort‐based study. Journal of Periodontology, 2023; 94(1): 98-107.
19. LIMONES A, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Medicina oral, patologia oral y cirugia bucal, 2020; 25(3): e326.
20. LIU F, et al. Jaw osteoporosis: Challenges to oral health and emerging perspectives of treatment. Biomedicine & Pharmacotherapy, 2024; 177: 116995.
21. MAUCERI R, et al. Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series. Oral, 2021; 1(4): 326-331.
22. MELZER RS, et al. A retrospective study of medication-related osteonecrosis of the jaw in multiple myeloma patients. Journal of bone marrow transplantation and cellular therapy, 2023; 4(3): 209-209.
23. MEREY SE, et al. Pentoxifylline and Tocopherol in the Management of Stage III Medication-Related Osteonecrosis of the Jaw: A Case Report. Akdeniz Diş Hekimliği Dergisi, 2023; 2(3):162-167.
24. MIRELLI C, et al. Medication-related osteonecrosis of the jaw in dental practice: A retrospective analysis of data from the Milan cohort. Dentistry Journal, 2022; 10(5): 89.
25. MORAES CM, et al. Osteonecrose dos maxilares associada ao uso dos bisfosfonatos: revisão de literatura. Revista saúde multidisciplinar, 2020; 8(2).
26. MORAIS RPL, et al. IS The use of pentoxifylline and tocopherol effective in the treatment of osteoradionecrosis of the jaws or for the treatment of medication-osteonecrosis of the jaw? an overview. Journal of Stomatology, Oral and Maxillofacial Surgery, 2024;101959.
27. OIZUMI T, et al. Osteonecrosis of the jaw in a patient treated with alendronate and then denosumab: A case of dramatic amelioration by minocycline and then etidronate. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2025; 37(2): 348-355.
28. RIVAS ANM, DONAIRE, JAR. Tratamiento conservador de osteonecrosis maxilar asociada a medicamentos refractaria mediante el uso de protocolo PENTO: reporte de un caso. Odontoestomatología, 2021: 23(38).
29. RUAN H. et al. Medication-related osteonecrosis of the jaw: a retrospective single center study of recurrence-related factors after surgical treatment. Clinical Oral Investigations, 2024; 28(10): 1-12.
30. RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. Journal of oral and maxillofacial surgery, 2022 80 (5): 920-943.
31. ŞAHIN O, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Brazilian Journal of Otorhinolaryngology, 2022; 88(4): 613-620.
32. SAKAMOTO Y, et al. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study. Scientific Reports, 2023; 13(1):12890.
33. SANTOS WB, et al. Osteonecrose dos Maxilares associada ao uso crônico de bisfosfonatos: relato de caso. Revista Eletrônica Acervo Saúde, 2020; 12(2): e2398.
34. SEO DD, BORKE, JL. Medication-Related Osteonecrosis of the Jaw–2024 Update. Oral Health Dental Sci, 2024; 8(1):1-6.
35. SHIN JW, et al. Radiological manifestations and clinical findings of patients with oncologic and osteoporotic medication-related osteonecrosis of the jaw. Scientific reports, 2024; 14(1): 8744.
36. SRIVASTAVA A, et al. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. Journal of Immunotherapy and Precision Oncology, 2021; 4(4): 196-207.
37. STRAUB A, et al. Bone concentration of ampicillin/sulbactam: a pilot study in patients with osteonecrosis of the jaw. International Journal of Environmental Research and Public Health, 2022; 19 (22): 14917.
38. VELASKI DP, et al. Etiopatogenia da osteonecrose maxilar relacionada a bisfosfonatos. Biosaúde, 2020; 22(2): 84-96.
39. WAN JT, et al. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone research; 2020; 8(1):14.
40. YAROM N, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. Journal of Clinical Oncology, 2019; 37(25): 2270-2290.